The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Keryx Biopharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference

Friday, August 31, 2012

Keryx Biopharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference08:30 EDT Friday, August 31, 2012Presentation Scheduled for Thursday, September 6th at 1:30pm ETNEW YORK, Aug. 31, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the Stifel Nicolaus 2012 Healthcare Conference, being held September 5-6, 2012, in Boston, MA.  Mr. Bentsur's presentation is scheduled to take place on Thursday, September 6, 2012 at 1:30pm Eastern Time.  A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.About Keryx Biopharmaceuticals, Inc.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City. KERYX CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail: lfischer@keryx.com  SOURCE Keryx Biopharmaceuticals, Inc.